Dr Reddys Laboratories (RDY) Non-Current Debt (2009 - 2026)

Dr Reddys Laboratories has reported Non-Current Debt for 18 years, with the latest figure at $150.7 million in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 153.03% year-over-year to $150.7 million in Q2 2026; TTM through Jun 2026 was $150.7 million, a 153.03% increase from a year earlier, with the FY2026 full-year figure at $130.0 million, up 41.3% from the prior year.
• Non-Current Debt was $150.7 million for Q2 2026 at Dr Reddys Laboratories, down from $199.2 million in the prior quarter.
• The five-year high for Non-Current Debt was $199.2 million in Q1 2026, with the low at $15.5 million in Q1 2023.
• Average Non-Current Debt over 5 years is $96.0 million, with a median of $84.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt sank 79.66% in 2023, then soared 363.95% in 2024.
• Over 5 years, Non-Current Debt stood at $75.5 million in 2022, then dropped by 2.08% to $73.9 million in 2023, then climbed by 21.49% to $89.8 million in 2024, then surged by 118.25% to $195.9 million in 2025, then dropped by 23.09% to $150.7 million in 2026.
• The last three Non-Current Debt figures came in at $150.7 million (Q2 2026), $199.2 million (Q1 2026), and $195.9 million (Q4 2025), per Business Quant data.